Summary
A new analysis from the DASISION trial showed that long-term treatment with dasatinib, compared with imatinib, in patients with treatment-naïve, chronic phase myeloid leukemia improved rates of major molecular response and molecular response, but not overall survival or progression-free survival, in the patients who completed 5 years of follow-up, without new safety signals.
- long-term treatment
- newly diagnosed chronic myeloid leukemia
- molecular response
- overall survival
- progression-free survival
- dasatinib
- imatinib
- Phase 3 Study of Dasatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Phase CML
- DASISION
- NCT00481247
- © 2014 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.